Related Experiment Video

Updated: Aug 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The HMG-CoA reductase pathway, statins and angioprevention

Chong Feng1, Anjia Han, Caisheng Ye

  • 1Sun Yat-sen University School of Medicine, Guangzhou GD, PRC.

Seminars in Ophthalmology
|March 7, 2006
PubMed

Insights

Statins, used for cholesterol, show promise in preventing tumor growth by inhibiting angiogenesis. These drugs promote endothelial cell death, offering a new strategy for cancer chemoprevention.

Area of Science:

  • Oncology
  • Cardiovascular Research
  • Molecular Biology

Background:

  • Angiogenesis is crucial for tumor development and a target for cancer chemoprevention.
  • Statins (HMG-CoA reductase inhibitors) are established drugs for hyperlipidemia and cardiovascular disease.
  • Emerging evidence suggests statins possess anti-angiogenic properties.

Purpose of the Study:

  • To review the biological effects of statins on endothelial cells and angiogenesis.
  • To explore the mechanisms underlying statin-mediated anti-angiogenesis.
  • To discuss the potential of statins in preventing pathological angiogenesis.

Main Methods:

  • Literature review of studies on statins, endothelial cells, and angiogenesis.
  • Analysis of research on molecular mechanisms of statin action.
  • Synthesis of current data on statin applications in cancer chemoprevention.

Main Results:

  • Statins inhibit experimental angiogenesis induced by growth factors or tumors.
  • Statins induce endothelial cell death, a key mechanism for anti-angiogenesis.
  • Statins demonstrate potential as angiopreventive agents.

Conclusions:

  • Statins exhibit significant anti-angiogenic effects.
  • Further research into statin-based strategies for pathological angiogenesis is warranted.
  • Statins represent a promising avenue for chemoprevention targeting tumor angiogenesis.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...